EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort

Jennie Engstrand iD, Per Stål, Stefan Gilg iD, Anders Jansson, Cecilia Strömberg iD

Scandinavian Journal of Surgery · 2024

DOI: 10.1177/14574969231220179 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Scandinavian Journal of Surgery, 2024. Verfasst von Jennie Engstrand und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgery Department of Clinical Science, Intervention and Technology (CLINTEC) Karolinska Institutet and Karolinska University Hospital 14…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Registries. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancerfonden, Bengt Ihres Foundation, Region Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims: Numerous studies have reported superior outcome for patients with hepatocellular carcinoma (HCC) in non-cirrhotic compared to cirrhotic livers. This cohort study aims to describe the clinical presentation, disease course, treatment approaches, and survival differences in a population-based setting.

Methods

Data on patients diagnosed with HCC in Sweden between 2008 and 2018 were identified and extracted from the Swedish Liver registry (SweLiv). Descriptive and survival statistics were applied.

Results

Among the 4259 identified patients, 34% had HCC in a non-cirrhotic liver. Cirrhotic patients presented at a younger age (median = 64 vs 74 years, p < 0.001) and with a poorer performance status (Eastern Cooperative Oncology Group (ECOG) = 0–1: 64% vs 69%, p = 0.024). Underlying liver disease was more prevalent among cirrhotic patients (81% vs 19%, p < 0.001). Tumors in non-cirrhotic livers were diagnosed at a more advanced stage (T3–T4: 46% vs 31%) and more frequently with metastatic disease at diagnosis (22% vs 10%, p < 0.001). Tumors were significantly larger in non-cirrhotic livers (median size of largest tumor 7.5 cm) compared to cirrhotic livers (3.5 cm) (p < 0.001). Curative interventions were more commonly intended (45% vs 37%, p < 0.001) and performed (40% vs 31%, p < 0.001) in the cirrhotic vs non-cirrhotic patients. Median survival was 19 months (95% confidence interval (CI) = 18–21 months), in patients with cirrhosis as compared to 13 months in non-cirrhotic patients (95% CI = 11–15) (p < 0.001). In the multivariable Cox regression model, cirrhosis was not an independent predictor of survival, neither among curatively nor palliatively treated patients.

Conclusion

These population-based data show that patients with HCC in a cirrhotic liver receive curative treatment to a greater extent and benefit from superior survival compared to those with HCC in a non-cirrhotic liver. The differences in survival are more attributable to patient and tumor characteristics rather than the cirrhotic status itself. Clinical trial registration: not applicable. Patient confidentially: not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisRegistriesHumansMaleFemaleMiddle AgedSwedenAgedSurvival RateAged, 80 and overAdultSurvival AnalysisCohort Studies

Stichwörter der Autor:innen

Hepatocellular carcinomacirrhosisnon-cirrhosis

Autor:innen und Institutionen

  • Division of Surgery Department of Clinical Science, Intervention and Technology (CLINTEC) Karolinska Institutet and Karolinska University Hospital 141 86 Stockholm Sweden.
  • Department of Gastroenterology and Hepatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Jennie Engstrand, Stefan Gilg, Cecilia Strömberg

Förderung

  • Cancerfonden
  • Bengt Ihres Foundation
  • Region Stockholm

Zitieren

APA

Engstrand, J., Stål, P., Gilg, S., Jansson, A., & Strömberg, C. (2024). Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort. Scandinavian Journal of Surgery. https://doi.org/10.1177/14574969231220179

Vancouver

Engstrand J, Stål P, Gilg S, Jansson A, Strömberg C. Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort. Scandinavian Journal of Surgery. 2024. doi:10.1177/14574969231220179

BibTeX
@article{Engstrand2024,
  author = {Engstrand, Jennie and Stål, Per and Gilg, Stefan and Jansson, Anders and Strömberg, Cecilia},
  title = {Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort},
  journal = {Scandinavian Journal of Surgery},
  year = {2024},
  doi = {10.1177/14574969231220179}
}
Kostenlos starten →